AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25433184 — intervention group
Group type: EXPERIMENTAL
Intervention: EBP CPE program alone (standard group)
Number of subjects: 580
Study 25433184 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 580
Study 21946819 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular outflow tract (RVOT) pacing
Number of subjects: 60
Study 21946819 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 60
Study 21142385 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (antibiotics and percutaneous drainage if necessary, with or without interval appendectomy)
Number of subjects: 15
Study 21142385 — intervention group
Group type: COMPARATOR
Intervention: Urgent appendectomy (control group)
Number of subjects: 15
Study 21142385 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment (study group)
Number of subjects: 15
Study 18328195 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1 percent cream plus clindamycin 1 percent gel
Number of subjects: 150
Study 18328195 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0.025 percent gel plus clindamycin 1 percent gel
Number of subjects: 150
Study 15809121 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural S(+)‐ketamine 0.1 mg/kg
Number of subjects: 56
Study 15809121 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 0.5 microg/kg
Number of subjects: 56
Study 15809121 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural S(+)‐ketamine 0.1 mg/kg plus epidural clonidine 0.5 microg/kg
Number of subjects: 56
Study 15809121 — intervention group
Group type: COMPARATOR
Intervention: Control group (epidural saline)
Number of subjects: 56
Study 15809121 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 56
Study 11903080 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined femoral and sciatic nerve block with obturator nerve block (5 ml 0.75% ropivacaine)
Number of subjects: 60
Study 11903080 — intervention group
Group type: COMPARATOR
Intervention: Combined femoral and sciatic nerve block (15 ml 0.75% ropivacaine to each nerve)
Number of subjects: 60
Study 9882786 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative autotransfusion (IAT)
Number of subjects: 100
Study 9882786 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 7727178 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care (UC)
Number of subjects: 72
Study 7727178 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups pooled
Number of subjects: 72
Study 7727178 — intervention group
Group type: COMPARATOR
Intervention: Dietary Intervention (D)
Number of subjects: 72
Study 7727178 — intervention group
Group type: COMPARATOR
Intervention: Diet plus cholestyramine (DC)
Number of subjects: 72
Study 2186661 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric aspiration at the end of anaesthesia
Number of subjects: 201
Study 2186661 — intervention group
Group type: COMPARATOR
Intervention: No gastric aspiration at the end of anaesthesia
Number of subjects: 201
Study 371545 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐28,888‐27
Number of subjects: 62
Study 371545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 31741126 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest model using conventional MRI sequences
Number of subjects: 142
Study 31741126 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest model using ADC images
Number of subjects: 142
Study 31741126 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model of T2WI FLAIR, post‐contrast T1WI, and ADC images
Number of subjects: 142
Study 31638338 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Number of subjects: 136
Study 31638338 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 136
Study 28454014 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouse allergen-targeted integrated pest management (IPM)
Number of subjects: 0
Study 28454014 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 0
Study 25754396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 1 mg
Number of subjects: 328
Study 25754396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 5 mg
Number of subjects: 328
Study 25754396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 10 mg
Number of subjects: 328
Study 25754396 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 25 mg
Number of subjects: 328
Study 25754396 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 328
Study 25754396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 328
Study 22540407 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (24 mg/day, reduced to 12 mg/day if needed for tolerability)
Number of subjects: 258
Study 22540407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 22540407 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 258
Study 23150126 — intervention group
Group type: EXPERIMENTAL
Intervention: Red pepper spice (1 g/d)
Number of subjects: 62
Study 23150126 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric (2.8 g/d)
Number of subjects: 62
Study 23150126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 19486960 — intervention group
Group type: EXPERIMENTAL
Intervention: Interoceptive exposure
Number of subjects: 6
Study 19486960 — intervention group
Group type: COMPARATOR
Intervention: Relaxation/distraction breathing-based technique
Number of subjects: 6
Study 17690257 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 17690257 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study 15519008 — intervention group
Group type: EXPERIMENTAL
Intervention: CrCl <60 ml/min
Number of subjects: 11187
Study 15519008 — intervention group
Group type: EXPERIMENTAL
Intervention: CrCl 60 to 89 ml/min
Number of subjects: 11187
Study 15519008 — intervention group
Group type: EXPERIMENTAL
Intervention: CrCl >89 ml/min
Number of subjects: 11187
Study 15519008 — intervention group
Group type: COMPARATOR
Intervention: CrCl groups
Number of subjects: 11187
Study 15519008 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD patients undergoing follow-up angiography
Number of subjects: 11187
Study 11225136 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 105
Study 11225136 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E capsules 400 units/day
Number of subjects: 105
Study 11225136 — intervention group
Group type: EXPERIMENTAL
Intervention: T. arjuna tree bark powder 500 mg daily
Number of subjects: 105
Study 9786807 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 138
Study 9786807 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study 7810184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of digoxin (0.8 mg)
Number of subjects: 11
Study 7810184 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 11
Study 2112083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous portal chemotherapy for 7 days
Number of subjects: 469
Study 2112083 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 469
Study 2112083 — intervention group
Group type: COMPARATOR
Intervention: Transfused patients with chemotherapy
Number of subjects: 469
Study 2112083 — intervention group
Group type: COMPARATOR
Intervention: Neither transfusions nor chemotherapy
Number of subjects: 469
Study 333608 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (cephalosporin, 2 gm/day in divided doses for 5 days)
Number of subjects: 77
Study 333608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 333608 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (cephalosporin)
Number of subjects: 77
Study 31845139 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg daily during the fasting period after ESD
Number of subjects: 235
Study 31845139 — intervention group
Group type: COMPARATOR
Intervention: Placebo during the fasting period after ESD
Number of subjects: 235
Study 31182183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (lecture and group work on impulsivity, 1.5 hours)
Number of subjects: 1441
Study 31182183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (female 5-HTTLPR s' allele carriers)
Number of subjects: 1441
Study 31182183 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (female DAT1 VNTR 10R/10R homozygotes)
Number of subjects: 1441
Study 31182183 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1441
Study 31182183 — intervention group
Group type: EXPERIMENTAL
Intervention: DAT1 VNTR 9R carriers (particularly males)
Number of subjects: 1441
Study 27837930 — intervention group
Group type: EXPERIMENTAL
Intervention: PneuX ETT
Number of subjects: 240
Study 27837930 — intervention group
Group type: COMPARATOR
Intervention: Standard ETT
Number of subjects: 240
Study 24903131 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised budesonide (800 μg)
Number of subjects: 0
Study 24903131 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised budesonide
Number of subjects: 0
Study 24903131 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (2 mg/kg)
Number of subjects: 0
Study 24903131 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone
Number of subjects: 0
Study 23945072 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim (6 mg subcutaneous injection on day 2 of each 21-day chemotherapy cycle)
Number of subjects: 202
Study 23945072 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim (6 mg subcutaneous injection on day 2 of each 21-day chemotherapy cycle)
Number of subjects: 202
Study 23945072 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim (control group)
Number of subjects: 202
Study 23945072 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim (experimental group)
Number of subjects: 202
Study 23945072 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim
Number of subjects: 202
Study 23945072 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim
Number of subjects: 202
Study 21773781 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH) with starting dose of 75-100 IU daily
Number of subjects: 189
Study 21773781 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) at 100 mg/day for 5 days
Number of subjects: 189
Study 21773781 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH)
Number of subjects: 189
Study 21773781 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 189
Study 19341123 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric treatment group (33 patients)
Number of subjects: 72
Study 19341123 — intervention group
Group type: COMPARATOR
Intervention: Sham control group (39 patients)
Number of subjects: 72
Study 19341123 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis
Number of subjects: 72
Study 15976213 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 15976213 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 30
Study 12598346 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based neoadjuvant chemotherapy
Number of subjects: 448
Study 10047639 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (40 to 60 mg/day)
Number of subjects: 19
Study 10047639 — intervention group
Group type: COMPARATOR
Intervention: Azosemide (60 to 90 mg/day)
Number of subjects: 19
Study 10047639 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 19
Study 10047639 — intervention group
Group type: COMPARATOR
Intervention: Azosemide
Number of subjects: 19
Study 7762839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (0.9 mg/kg)
Number of subjects: 54
Study 7762839 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (2 mL)
Number of subjects: 54
Study 7762839 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1 microgram/kg)
Number of subjects: 54
Study 2137888 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine A (CSA)
Number of subjects: 49
Study 2137888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 7000260 — intervention group
Group type: EXPERIMENTAL
Intervention: Single daily injections of insulin (Monotard plus Actrapid)
Number of subjects: 15
Study 7000260 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily injections of insulin (Semitard plus Actrapid)
Number of subjects: 15
Study 11974458 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic therapy for palliation by ablation, dilatation, or stenting
Number of subjects: 0
Study 11974458 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment of postoperative complications
Number of subjects: 0
Study 11974458 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment of anastomotic strictures
Number of subjects: 0
Study 11974458 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional flexible endoscopy
Number of subjects: 0
Study 11974458 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficient detection of locoregional recurrence
Number of subjects: 0
Study 30252113 — intervention group
Group type: EXPERIMENTAL
Intervention: Life stress interview (90 minutes)
Number of subjects: 62
Study 30252113 — intervention group
Group type: COMPARATOR
Intervention: No interview (treatment-as-usual control)
Number of subjects: 62
Study 29784890 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention
Number of subjects: 172
Study 26646854 — intervention group
Group type: EXPERIMENTAL
Intervention: Code-word alarm
Number of subjects: 353
Study 26646854 — intervention group
Group type: COMPARATOR
Intervention: Control (commercially available wireless alarm)
Number of subjects: 353
Study 24866527 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vocal responses to moral transgressions
Number of subjects: 2
Study 24866527 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vocal responses to prudential transgressions
Number of subjects: 2
Study 24866527 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vocal responses to pragmatic transgressions
Number of subjects: 2
Study 23074932 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar TUR
Number of subjects: 198
Study 23074932 — intervention group
Group type: COMPARATOR
Intervention: Quasibipolar TUR
Number of subjects: 198
Study 20446503 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 0
Study 20446503 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 0
Study 20446503 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Training (NT)
Number of subjects: 0
Study 17512015 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O and oxygen inhalation (group 1)
Number of subjects: 28
Study 17512015 — intervention group
Group type: COMPARATOR
Intervention: Air and oxygen mixture (group 2)
Number of subjects: 28
Study 16240961 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (SE)
Number of subjects: 32
Study 16240961 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop (PLP)
Number of subjects: 32
Study 16240961 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper (AD)
Number of subjects: 32
Study 16240961 — intervention group
Group type: COMPARATOR
Intervention: 35% phosphoric acid (control)
Number of subjects: 32
Study 11906359 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose subcutaneous birch pollen immunotherapy (IT)
Number of subjects: 35
Study 11906359 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 35
Study 10434231 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir 360 mg
Number of subjects: 18
Study 10434231 — intervention group
Group type: COMPARATOR
Intervention: Oral ganciclovir 1000 mg
Number of subjects: 18
Study 10434231 — intervention group
Group type: COMPARATOR
Intervention: Intravenous ganciclovir 5 mg/kg
Number of subjects: 18
Study 7573783 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg alcohol
Number of subjects: 29
Study 7573783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2140848 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral loading with L-tryptophan
Number of subjects: 25
Study 2140848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressant treatment
Number of subjects: 25
Study 375865 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study 375865 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (Thorazine)
Number of subjects: 0
Study 375865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31064974 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CP adjusted every 30 minutes using N₂O)
Number of subjects: 84
Study 31064974 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group 1 (CP adjusted every 10 minutes using N₂O)
Number of subjects: 84
Study 31064974 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group 2 (non‐adjusted CP using air)
Number of subjects: 84
Study 28763350 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic harvesting of the radial artery
Number of subjects: 119
Study 28763350 — intervention group
Group type: COMPARATOR
Intervention: Conventional harvesting of the radial artery
Number of subjects: 119
Study 25456867 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolastin C (human plasma-derived AAT) at 60 mg/kg infused intravenously within 12 hours of admission
Number of subjects: 10
Study 24035369 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid adhesive ocular bandage (Ocuseal)
Number of subjects: 90
Study 24035369 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐0 nylon suture
Number of subjects: 90
Study 24035369 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (control)
Number of subjects: 90
Study 21853425 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole (group A)
Number of subjects: 50
Study 21853425 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole nasal spray (group B)
Number of subjects: 50
Study 21853425 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral itraconazole and nasal fluconazole (group C)
Number of subjects: 50
Study 21853425 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation with fluconazole solution (group D)
Number of subjects: 50
Study 21853425 — intervention group
Group type: COMPARATOR
Intervention: Convenient medical treatment only (group E)
Number of subjects: 50
Study 19663129 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI, 80/4.5 microg (320/18 microg/d) twice daily
Number of subjects: 619
Study 19663129 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI, 160/4.5 microg (320/9 microg/d) once daily
Number of subjects: 619
Study 19663129 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI, 80/4.5 microg (160/9 microg/d) once daily
Number of subjects: 619
Study 19663129 — intervention group
Group type: COMPARATOR
Intervention: Budesonide pMDI, 160 microg (320 microg/d) once daily
Number of subjects: 619
Study 19663129 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 619
Study 16323085 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir (1000 mg given twice daily)
Number of subjects: 0
Study 16323085 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12872795 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry (Nerve Fiber Analyzer [NFA] GDx) in patients with PDS
Number of subjects: 56
Study 12872795 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry (Nerve Fiber Analyzer [NFA] GDx) in patients with PG
Number of subjects: 56
Study 10807120 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid demineralization
Number of subjects: 36
Study 10807120 — intervention group
Group type: COMPARATOR
Intervention: No citric acid demineralization (Control)
Number of subjects: 36
Study 8880078 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms CCK4
Number of subjects: 12
Study 1824707 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17 beta-estradiol (Estraderm; 0, 50, 100, or 150 micrograms/day) combined with oral medroxyprogesterone acetate (10 mg each day) during weeks 3-4 and 7-8 of each 8-week regimen
Number of subjects: 28
Study 6851041 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (360 mg/day)
Number of subjects: 13
Study 30628953 — intervention group
Group type: EXPERIMENTAL
Intervention: Shanghai growth standards (S-group)
Number of subjects: 15019
Study 30628953 — intervention group
Group type: COMPARATOR
Intervention: WHO 2006 growth standards (W-group)
Number of subjects: 15019
Study 28746186 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-based PIV score assessment with MDT for patients with PIV <8
Number of subjects: 58
Study 28746186 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone for patients with PIV >=8
Number of subjects: 58
Study 28746186 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival for optimal cytoreduction
Number of subjects: 58
Study 25985858 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Number of subjects: 20
Study 25985858 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-neurofeedback
Number of subjects: 20
Study 23288870 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/ezetimibe 10/10 mg
Number of subjects: 50
Study 23288870 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 50
Study 22024001 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 89
Study 19405936 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with concurrent chemotherapy (docetaxel)
Number of subjects: 0